Stockscreener 앱 받기
0.0201
30.45%
-0.0088
시장 영업 전:
.02
-0.000100
-0.50%
Elevai Labs Inc 주식(ELAB)의 최신 뉴스
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire
Elevai Labs strikes new executive agreements - Investing.com India
Elevai Labs strikes new executive agreements By Investing.com - Investing.com UK
Elevai Biosciences gears up for obesity drug IND submission By Investing.com - Investing.com Nigeria
Elevai Biosciences gears up for obesity drug IND submission - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., - GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - Yahoo Finance UK
Elevai reports promising preclinical obesity treatment results By Investing.com - Investing.com South Africa
Elevai reports promising preclinical obesity treatment results - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - The Manila Times
ELAB stock’s current quarter earnings estimates: What analysts predict? - US Post News
Elevai Labs Inc. Inc. (ELAB) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Metric Deep Dive: Understanding Elevai Labs Inc. (ELAB) Through its Ratios - The Dwinnex
Insider’s View: Deciphering Elevai Labs Inc. (ELAB)’s Financial Health Through Ratios - The Dwinnex
Views of Wall Street’s Leading Experts on Elevai Labs Inc. - SETE News
Elevai Labs Inc. [ELAB] is -94.09% lower this YTD. Is it still time to buy? - The DBT News
Elevai Labs Inc. (ELAB) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - ForexTV.com
Elevai Labs Inc. Commences Offer to Exchange Up to - GlobeNewswire
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - ForexTV.com
Elevai files patents for obesity treatment EL-22 By Investing.com - Investing.com Australia
Elevai files patents for obesity treatment EL-22 - Investing.com
This tiny skincare company is up big 💪 - RagingBull
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - StockTitan
Elevai Labs commences exosome skincare study By Investing.com - Investing.com South Africa
Elevai Labs commences exosome skincare study - Investing.com India
ELABElevai Labs, Inc. Latest Stock News & Market Updates - StockTitan
Elevai Labs begins clinical study of topical exosome product - TipRanks
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., - GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining - The Bakersfield Californian
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device - StockTitan
Check out these key findings about Elevai Labs Inc. (ELAB) - SETE News
ELAB Stock Update: Elevai Labs Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
What is ELAB’s price-to-sales ratio telling us about the company’s value? - US Post News
Elevai Labs Inc. [ELAB] Revenue clocked in at $2.47 million, down -94.95% YTD: What’s Next? - The DBT News
In the Green: Elevai Labs Inc. (ELAB) Closes at 0.09, Up/Down 3.71 from Previous Day - The Dwinnex
Elevai Labs Inc.’s Banking’s 100-Day Moving Average at 0.4636: Will the Stock Break Through? - The InvestChronicle
Biotech Alert: Searches spiking for these stocks today - TipRanks
Altium Capital Management LP Acquires New Stake in Elevai Labs Inc - Yahoo Finance
Elevai Labs stock offering raises $8 million - Sacramento Business Journal
Univest Securities, LLC Announces Closing of $8.0 Million - GlobeNewswire
Elevai Labs announces pricing of $8 million public offering - MSN
Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) - ForexTV.com
Evolus Inc (EOLS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Evolv Technologies (NASDAQ:EVLV) Shares Down 2.9% - Defense World
EverSource Wealth Advisors LLC Raises Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down to $23.57 - MarketBeat
Logos Global Management LP Lowers Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
First Light Asset Management LLC Has $27.63 Million Stake in Evolent Health, Inc. (NYSE:EVH) - Defense World
Evolv Technologies Holdings Inc (EVLV) looking to reclaim success with recent performance - SETE News
Stock Market Recap: Evolus Inc (EOLS) Concludes at 15.53, a -6.16 Surge/Decline - The Dwinnex
Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News
SEC Form 424B3 filed by Elevai Labs Inc. - Quantisnow
Lombard Odier Asset Management Europe Ltd Invests $2.51 Million in Elevance Health, Inc. (NYSE:ELV) - Defense World
5.11%
0.50%
자본화:
|
볼륨(24시간):